cardiovascular research News
-
BOC Sciences Outlines Its Contribution of Peptides to Cardiovascular Research
BOC Sciences' monthly report released in August showed that its peptide products had vastly facilitated the R&D of cardiovascular therapies. February is set as American Heart Month since heart disease is the number one cause of death for most groups, affecting all ages, genders, and races. More than 600,000 Americans die from heart disease every year. The striking fact drives a great deal ...
By BOC Sciences
-
Puzzle Medical Devices Inc. Wins TCT 2022 Shark Tank Innovation Competition
The Cardiovascular Research Foundation (CRF) is pleased to announce that Puzzle Medical Devices Inc. has won the TCT 2022 Shark Tank Innovation Competition for its novel circulatory support device that is implanted percutaneously in the abdominal aorta. The competition took place during Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier educational meeting specializing in ...
-
Infraredx, a Nipro Company, Announces FDA Approval of Expanded Label Claim for the Makoto Intravascular Imaging System
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the indications for use for its Makoto Intravascular Imaging System. The approval is based on the results of the landmark Lipid-Rich Plaque (LRP) Study, which demonstrated the ability of ...
-
CARMAT announces the second center implanting its total artificial heart in the United States
The implant was performed at UofL Health – Jewish Hospital by University of Louisville physicians within the framework of the U.S. Early Feasibility Study. CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage ...
By Carmat
-
Alucent Biomedical Announces First Patient Enrolled in Phase 1 Natural Vascular Scaffolding Clinical Trial
Alucent Biomedical Inc. announced that it has enrolled the first two patients in ACTIVATE I, a Phase 1 clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (NVS) technology. The therapy is designed to open vessels and keep them open without the use of permanent implants in the treatment of peripheral artery disease (PAD) of the lower extremities, a ...
-
Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2022
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be attending the American Heart Association Scientific Sessions (AHA) at McCormick Place Convention Center in Chicago, IL from November 5-7th, 2022. “The AHA Scientific Sessions is a leading event connecting over 15,000 experts from over one hundred countries focused on ...
-
Insurance auto auctions` one car one difference(TM) car donation program adds four more
Four additional nationally recognized organizations have been added as benefactors of One Car One Difference™, a new program to help charities raise funds for medical research and to provide food, medicine, and shelter to people and animals in need by encouraging the public to donate old cars through a hassle-free donation process. The program, which officially launches this month, will be ...
-
1st MitraClip Procedure Guided by 4D Performed at UC Davis Health
Sacramento, CA – The first MitraClip procedure using EchoPixel’s Holographic Therapy Guidance (HTG) was performed by Structural Heart Physicians at UC Davis Health. The image acquisition was led by Edris Aman M.D. while the procedure was performed and HTG guidance utilized by Gagan Singh, M.D., director, Cardiovascular Research Unit. MitraClip is a procedure that approximates ...
-
New Data Confirms Cardiac Dimensions’ Carillon System Shows Favorable Long-Term Survival Rate in Patients with Functional Mitral Regurgitation
Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the findings of a post hoc analysis of pooled prospectively collected data from three studies of the Carillon Mitral Contour System® with a focus on 5-year survival rate and the determinants of long-term ...
-
Tales from TCT 2019: Ancora’s Heart Felt Data
During the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, Santa Clara, CA-based Ancora presented interim study results from systolic heart failure patients treated with AccuCinch, a percutaneous therapy designed to improve left ventricular function. A stronger and more experienced Ancora Heart entered into the 31st Transcatheter Cardiovascular Therapeutics (TCT), ...
-
Landmark Lipid-Rich Plaque (LRP) Study Results Demonstrate the Ability to Accurately Identify Patients and Plaques at Risk for Major Coronary Events
Infraredx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, presented late-breaking clinical trial results for its landmark Lipid-Rich Plaque (LRP) Study today at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. Cardiovascular disease remains the number one cause of death globally, ...
-
Lungpacer Medical Accelerates Pivotal Clinical Study with AeroPace™ System
Lungpacer Medical, a leading medical device innovation company, today announced the introduction of the AeroPace™ System, a next generation product, into the RESCUE 3 pivotal clinical study studying faster ventilator independence. Lungpacer is dedicated to natural breathing by developing minimally invasive technologies designed to help patients wean off mechanical ventilation and breathe on ...
-
Results of the PROSPECT II Natural History Study Demonstrate High-Risk Plaques Identified by NIRS+IVUS Imaging are Linked to Future Coronary Events
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced positive results from the PROSPECT II and PROSPECT ABSORB studies, presented today as a late-breaking clinical trial at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation. The PROSPECT II study demonstrated the ability of near-infrared spectroscopy ...
-
Saranas® Announces Initial Enrollment of Clinical Trial Assessing the Utility of Early Bleed Detection in Patients Undergoing Mechanical Circulatory Support
Saranas, Inc., has announced initiation and first patient enrollment in SAFE-MCS, a multi-center, single arm, open-label clinical trial evaluating the safety of complex high-risk percutaneous coronary intervention (PCI) using mechanical circulatory support (MCS) and surveillance with the Early Bird Bleed Monitoring System. The first patient was enrolled at Atlantic Health System’s ...
-
Shockwave Medical Initiates All-Female Coronary IVL Study
EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions Study Seeks to Confirm Benefits of Shockwave’s Coronary IVL in Females Who Historically Have Suffered Less Favorable Clinical Outcomes than Male Patients with Traditional Therapies Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely ...
-
BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial
BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz (Germany) has joined the European REVIVE-HF clinical trial of the Revivent TC™ Transcatheter Ventricular Enhancement System as co-principal investigator. Dr. von Bardeleben heads ...
-
Vektor Medical to Present Positive Results from vMap Clinical Validation Study Showing 97.3% Mapping Accuracy for Atrial and Ventricular Arrhythmias
Non-invasive arrhythmia technology maps using only the data from a 12 lead ECG vMap provides actionable mapping results in minutes. Blinded, multi-center study with analysis by an independent core laboratory Results to be presented for the first time at Heart Rhythm 2022 Vektor Medical today announced positive results from its “Vektor vMap™ Clinical Validation ...
-
New Phase III study to investigate expanded use of vericiguat in patients with chronic heart failure with reduced ejection fraction
New Phase III study VICTOR will assess vericiguat efficacy and safety in patients who have not had a recent worsening heart failure event / VICTOR expands upon the Phase III VICTORIA study, providing further insight into the use of vericiguat in a broader range of patients with chronic heart failure with reduced ejection fraction Bayer and its development partner MSD (a tradename of Merck & ...
By Bayer AG
-
InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body
InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, announced the publication of the first comprehensive analysis providing significant support for the existence of naturally pluripotent stem cells in all organs. Pluripotent stem cells have the ability to become any cell type of the adult body. The newly-released publication, entitled “Perspective: Why and How ...
-
Osso VR and American College of Cardiology to Develop Immersive Training for Cardiovascular Professionals
Osso VR, now the largest and fastest-growing virtual reality (VR) company in healthcare, and the American College of Cardiology (ACC), a global nonprofit dedicated to transforming cardiovascular care, today announced a new collaboration to develop an immersive, VR-enabled training program for cardiovascular professionals. The collaboration builds upon the ACC’s long tradition of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you